PETALUMA --  Oculus Innovative Sciences reported total revenue of $2.2 million in the fourth quarter of fiscal 2010, an increase of 51 percent over $1.5 million in the fourth quarter of fiscal 2009.

     Product revenue was $2 million, up 65 percent from $1.2 million in the prior fourth quarter primarily due to higher sales in the United States, Mexico, China, India and the Middle East.

Operating expenses for the quarter were down 9 perent from the same period last year and in line with previous guidance.

Oculus Innovative Sciences is a commercial medical technology company that designs, produces and markets tissue care products based upon the Microcyn Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing.